Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer 2021-11-16 00:00
PNOC Study in Childhood Brain Cancer Enrols First Patient 2021-11-11 21:00
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial 2021-11-04 08:38
Kazia Therapeutics to Present at LD Micro Main Event 2021-10-06 22:00
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference 2021-09-11 00:30
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day 2021-07-21 22:00
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs 2021-06-30 22:00
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma 2021-06-15 22:00
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient 2021-06-07 20:00
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE 2021-04-19 17:54
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company 2021-03-29 17:43
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB 2021-03-02 07:00
Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG 2020-12-10 12:51
Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals 2020-12-09 07:49
Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma 2020-11-18 07:39
Kazia Executes Agreement To Commence GBM Agile Pivotal Study 2020-10-16 07:30
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma 2020-09-22 09:21
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG 2020-08-24 09:14
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma 2020-08-20 08:35
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG 2020-08-07 08:30
1 2 3 4